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DAPI   4',6-Diamidino-2-Phenylindole 
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Infectious diseases continue to threaten human and animal health and welfare globally, 
impacting millions of lives and causing substantial economic loss. The discovery and 
administration of antibacterials have only been partially successful in reducing disease impact. 
Bacterial cells are inherently resilient and the therapy challenge is increased by the 
development of antibacterial resistance, the formation of biofilms and the ability of certain 
clinically important pathogens to invade and localize within host cells. Invasion into host cells 
provides protection from both antibacterials and the host immune system. Poor delivery of 
antibacterial into host cells causes inadequate bacterial clearance, resulting in chronic and 
unresolved infections. In this review, we discuss the challenges associated with existing 
antibacterial therapies with a focus on intracellular pathogens. We consider the requirements 
for successful treatment of intracellular infections and novel platforms currently under 
development. Finally, we discuss novel strategies that give promise for the treatment of bacteria 
that present challenges to antibacterial penetration into host cells. As an example, we discuss 
our recent demonstration that the cell penetrating cationic polymer polyhexamethylene 
biguanide has antibacterial activity against intracellular Staphyloccocus aureus.  
 




Antibacterial resistance and the challenge of infectious disease 
Infectious disease remains a major threat to both human and animal populations. In the human 
population in 2010 approximately 15 million deaths were due to infectious disease, and the 
World Health Organization (WHO) forecasts that this figure will fall only marginally by 2050 
(Dye, 2014). In the animal population, infectious disease continues to affect the health and 
welfare of livestock, resulting in threats to food security. This situation not only causes huge 
economic losses but also increases the risk of possible transmission of zoonotic disease to the 
human population (Tomley and Shirley, 2009).  
 
The discovery of penicillin as an antibacterial in the early 20th century revolutionized treatment 
for infectious diseases caused by bacteria (Fleming, 1929). Soon after, chloramphenicol, 
streptomycin and several other antibiotics provided further therapy options. It is without doubt 
that although the discovery and development of antibacterials improved infectious disease 
control, the triumph of antibacterial therapy has been short-lived. Increasing consumption of 
antibacterials to treat illnesses, the use of antibacterials as growth promoters in livestock and 
their un-controlled released into nature introducing continuous selective pressures, has resulted 
in the development of resistance (Dye, 2015, Tomley and Shirley, 2009). The World Economic 
Forum recently concluded that antibacterial resistance is the greatest risk to human health 
(Howell, 2013). Many infections are now difficult to treat, resulting in high dose administration 
of antibacterials, in-tolerable toxicity and delays in effective treatment (WHO, 2012). It has 
been estimated that infections by antibacterial resistant pathogens claim a total of 700,000 lives 
every year globally, with 10 million projected deaths in the year 2050 (O’Neill, 2014). 
 
The impact of antibacterial resistance is also important within animal health. In livestock a high 
prevalence of beta-lactam resistant Staphylococcus aureus, one of the pathogens responsible 
for bovine mastitis has made existing therapies less effective, prolonging the disease and 
increasing the costs of treatment (Barkema et al., 2006). Also, in companion animals the 
emergence of methicillin-resistant Staphylococcus pseudointermedius (MRSP), the causative 
agent of skin, ear and wound infections is a new challenge for veterinary medicine (van 
Duijkeren et al., 2011). 
 
Conventionally bacteria become resistant to antibiotics through the acquisition of resistance 
traits. A classic example of this is the acquisition of beta-lactamases, which are hydrolytic 
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enzymes that break down beta-lactam antibiotics rendering them ineffective. However, the 
acquisition of resistance traits is only one of the contributing factors in treatment failure. For 
an antibacterial to be effective in the clinic, it should be able to reach both the bacteria and its 
molecular targets at effective concentrations that are not toxic to the host. It has been 
recognized for some time that infections with Gram -ve bacteria can be difficult to treat, 
because the outer membrane provides a barrier against the diffusion of antibacterials. At the 
population level, the ability of bacterial communities to form biofilms also provides barriers to 
drug penetration. These three dimensional multicellular aggregates are inherently resistant to 
antibacterials. The formation of biofilms by S. aureus on medical devices, such as artificial 
joints or catheters, and Pseudomonas aeruginosa on the surfaces of infected sites can bring 
additional hurdles to existing therapies (McConoughey et al., 2014; Winstanley et al., 2016). 
In the case of bovine mastitis, biofilm formation by S. aureus on the mammary gland reduces 
the effectiveness of therapies, creating persistent infections (Melchior, 2011). For detailed 
knowledge on biofilms and their clinical burden, readers are invited to refer to the following 
extensive review (Abee et al., 2011). 
 
Biofilms present challenges in terms of the access antibacterial to their bacterial targets. In this 
review we focus on another similar and equally significant challenge to successful therapy; the 
problem of antibacterial gaining access to bacteria residing within host cells. 
 
Intracellular bacteria represent hard to reach targets 
Certain species of bacteria are able to localize inside host cells, followed by multiplication and 
modulation of the host cell biology. In this way, these bacteria create a niche, from which they 
can continue the infection cycle (Silva and Silva Pestana, 2013). This group of bacteria, known 
as intracellular bacteria, can also manipulate the host immune system to permit dissemination 
to different sites of the body. The classical examples of intracellular bacteria are 
Mycobacterium tuberculosis, Salmonella enterica, Chlamydia trachomatis, and Listeria 
monocytogenes (Armstrong and Hart, 1971; Ibarra and Steele-Mortimer, 2009; Kumar et al., 
2006; Gaillard et al., 1987). Additionally, evidence suggests that some classical extracellular 
bacteria, such as S. aureus, Escherichia coli and P. aeruginosa also have the ability to invade 
and localize inside host cells (Dikshit et al., 2015; Garzoni and Kelley, 2009; Angus et al., 
2008).  Table 1 provides a list of intracellular bacteria and their associated disease. Below we 
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discuss the mechanisms of invasion used by three clinically important pathogens, S. enterica, 
M. tuberculosis and S. aureus. 
 
Salmonella enterica  
Host infections start when S. enterica is ingested. On reaching the gastrointestinal tract, S. 
enterica can induce its own uptake into specialized epithelial cells, M cells, that cover Peyer’s 
patches of the intestine (Jensen et al., 1998). The bacteria injects effector proteins into the host 
cell, triggering membrane ruffling and actin rearrangement from inside the cells, leading to 
bacterial internalization (Patel and Galán, 2005). Internalization into M cells allows the bacteria 
to cross the intestinal barrier. The bacteria are then engulfed by macrophages and reside in a 
phagosome called the salmonella containing vacuole. While inside vacuoles, S. enterica secrete 
effector proteins that can prevent fusion of the phagosome with a lysosome, therefore avoiding 
lysosomal activities within macrophage (Gorvel and Méresse, 2001). Recent evidence also 
suggests that S. enterica can escape into the cytosol (Brumell et al., 2002). Migration of 
infected macrophages can further disseminate bacteria into other organs, such as the liver and 
spleen (Monack et al., 2004).  
 
Mycobacterium tuberculosis 
Transmission of M. tuberculosis occurs via inhalation of droplets containing the bacilli. Once 
the pathogen reaches the lung airways, bacteria are phagocytosed by alveolar macrophages. 
Numerous studies show that M. tuberculosis can evade the killing process in macrophages by 
arresting phagosome fusion with the lysosome, thereby establishing a survival niche within 
macrophages where replication occurs (Armstrong and Hart, 1971; Rohde et al., 2012). 
However, more recent studies demonstrate that certain M. tuberculosis strains can escape into 
the cytosol, by permeabilizing the phagosome membrane (Watson et al., 2012). 
 
Staphylococcus aureus 
S. aureus is a Gram-positive pathogen that can cause various disease conditions including 
complicated skin infections (Dryden, 2010) and bloodstream infections in hospitalized patients 
(hospital acquired infections) (Burton et al., 2009). In animals, S. aureus is one of the main 
pathogens that causes mastitis, a disease manifested by inflammation of the udder (Jamali et 
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al., 2014). S. aureus was historically known as an extracellular bacterium until recently. 
However, accumulating evidence suggests that this bacteria can invade and survive in various 
host cells including keratinocytes, endothelial cells, epithelial cells, fibroblast, osteoblasts and 
bovine mammary epithelial cells (Mempel et al., 2002; Garzoni et al., 2007; Sinha and 
Hermann 2005; Hanses et al., 2011; Reott et al., 2008; Hébert et al., 2000). 
 
S. aureus invades host cells through a zipper uptake mechanism involving adhesion  to the host 
cell surface (Fraunholz and Sinha, 2012). Attachment leads to signal transmission that results 
in cytoskeletal rearrangement, allowing movement of S. aureus into host cells (Sinha et al., 
1999; Ahmed et al., 2001; Edwards et al., 2011). Once inside the host cell, S. aureus can either 
survive and replicate within the acidic phagolysosome (Brouillette et al., 2003) or escape from 
the phagosome into the cytosol (Fraunholz and Sinha, 2012). S. aureus invasion can induce 
cell death, allowing the bacteria to escape and start a new cycle of infection, subsequently 
entering the blood stream to cause septicemia (Soong et al., 2012). 
 
The problem of antibacterial delivery to bacteria residing within host cells is of paramount 
importance. Some of these bacteria are responsible for devastating diseases. For example, M. 
tuberculosis, the causative agent of tuberculosis, causes approximately 1.5 million deaths per 
year and is the second leading cause of death due to a single infectious agent (Lewandowski et 
al., 2015). Species belonging to the Salmonella group are important foodborne pathogens 
responsible for enteric diseases and cause over one billion infections annually (Buckle et al., 
2012). Moreover, methicillin-resistant Staphylococcus aureus (MRSA) is responsible for 20% 
of mortality due to the blood stream infections in the hospital-acquired setting (Thomer et al., 
2016). Therefore, the effective delivery of antibacterial into host cells containing these 
pathogens is a critical goal of novel antibacterial therapies. 
 
Current challenges in the treatment of intracellular bacterial infections 
The delivery of antibacterials into desired locations in the body is one of the main challenges 
for successful therapeutics. Depending on the routes of uptake and the location of the 
infections, antibacterials may need to cross the epithelial cells of the gastrointestinal tract to 
reach the bloodstream (oral antibacterial), the thick stratum corneum for skin infections (topical 
antibacterial), and the mucosa for respiratory tract infections (pulmonary antibacterial).  
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For infections that are caused by pathogens that reside extracellularly, antibacterials can exert 
activities rapidly. However, if bacteria reside intracellularly, antibacterials face another 
challenge; they need to cross the host cell membrane either through diffusion or endocytosis. 
Localization of bacteria inside host cells provides protection and, although there are multiple 
antibacterials options available for treatment, more than two thirds are ineffective against 
intracellular pathogens (Abed and Couvreur, 2014). 
 
The plasma membrane of mammalian cells is composed of a lipid bilayer embedded with 
peripheral and integral proteins, and is impermeable to most polar or charged solutes. Small (< 
700 Da in size) lipophilic antibacterials such as beta lactams, macrolides and quinolones enter 
mammalian cells via diffusion across the lipid bilayer (Tulkens, 1991). Uptake via endocytosis 
occurs when a compound is large or does not readily diffuse across the membrane. Endocytosis 
involves internalization of molecules bound within vesicles from the membrane, followed by 
invagination of the vesicles into the host cells. Once taken up by the host cells, the vesicles are 
directed to the endosomal route, where acidification takes place. Certain compounds can trigger 
membrane destabilization, therefore are released into the cytosol of the host cell.  
 
Aminoglycoside antibiotics are known to enter host cells via endocytosis. They bind to 
megalin, the endocytic receptor abundantly expressed in the renal proximal tubule that 
promotes uptake into the host cells (Nagai and Takano, 2004). Because of the specificity of 
aminoglycoside towards megalin, accumulation of the antibiotics in the kidney can cause 
nephrotoxicity in patients (Nagai and Takano, 2004).  
 
Once inside the host cells, antibacterials have to be retained and accumulate at sufficient 
concentrations for a period that is sufficient to exert their effects. Although macrolide and 
quinolone can enter the host cells via diffusion, they are subjected to P-glycoprotein efflux 
pumps, leading to reductions in antibiotic accumulation inside the host cells (Seral et al., 2003). 
For compounds entering the host cell via endocytosis, if the compound remains in the 
endosome, it will be exported out from the host cell via the exocytosis route. 
In addition to penetration and retention inside host cells, to be effective, antibacterials must 
also reside within the same sub-cellular compartment as their bacterial target. As discussed 
previously, intracellular bacteria can reside within intracellular compartments or the cytosol. 
Therefore, antibacterial must penetrate the specific compartment where bacteria are residing. 
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The choice of intracellular location (vesicle or cytosol) brings additional challenges to 
treatment. Certain bacteria such as Salmonella localize and replicate in acidified phagosomes 
where the pH is in between 4-5.5. Therefore to be active against intracellular bacteria selected 
antibacterials must also resist pH insult (Lemaire et al., 2011). 
 
To adapt to the stress of the host cell environment, intracellular bacteria transform their 
physiological condition to a non-replicating or slowly replicating state (Grant and Hung, 2014). 
S. enterica can change into a state of non-replicating persistence inside macrophages and, S. 
aureus can change into small colony variants inside epithelial cells (Helaine et al., 2014; Vesga 
et al., 1996). Changes in their physiology make these variants less susceptible to antibacterials 
that are often only active against the variants with normal growth rates (Nguyen et al., 2009). 
M. tuberculosis enters a non-replicating state within the host to cause latent infections that are 
resistant to conventional treatment (Wayne and Sohaskey, 2001). Therefore, to be able to clear 
intracellular infections by non-replicating bacteria, antibacterial must be effective against both 
replicating and non-replicating states. 
 
The potency of existing therapies for intracellular infections 
Quinolones are often considered to be the best choice for treatment of intracellular infections. 
They have potent activities against a range of Gram +ve and Gram -ve bacteria and 
mycobacteria (Hartley 2011; Jacobs, R, 1999). They enter and accumulate in mammalian cells 
(Tulkens, 1991) and diffuse across subcellular compartments (Carlier et al., 1990). Although 
quinolones have been shown to be more effective against intracellular bacteria, compared to 
other classes of antibacterials (Carryn et al., 2003), their potency against bacteria that are 
located intracellularly is still much lower relative to their potency against extracellular bacteria 
(Seral et al., 2005).  
 
Derivatives of tetracycline, such as tigecycline, have also shown efficacy against intracellular 
bacteria. This antibiotic has potent activities against a range of Gram +ve and Gram -ve bacteria 
(Peterson, 2008). Tang et al., 2011 demonstrated bactericidal activities of tigecycline at 0.5 
mg/L against intracellular S. typhimurium in peripheral blood mononuclear cells (Hung-Jen 
Tang et al., 2011). In contrast, another study found that tigecycline at 1 mg/L, demonstrated 
only bacteriostatic activities against intracellular S. aureus in polymorphonuclear neutrophils 
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(Ong et al., 2005). These observations provide examples of how intracellular localization 
influences the activity of antibacterials. 
 
Existing antibiotics can be improved by increasing their ability to penetrate host cells. Barcia-
Macay et al., 2006 made a comparison between vancomycin and televancin (a hydrophobic 
derivative of vancomycin), against intracellular S. aureus in macrophages. Televancin 
displayed bactericidal activities against intracellular S. aureus within six hours of treatment, 
while vancomycin required 24 hours to demonstrate the same efficacy (Barcia-Macay et al., 
2006). The reduced efficacy of existing antibiotics has driven the need to improve existing 
therapies. Some of the many platforms that can potentially improve the outcome and provide a 
better solution for intracellular infections are discussed below. 
 
Novel promising therapies in the treatment of intracellular infections 
Antimicrobial peptides 
Antimicrobial peptides (AMP) are chains of amino acids produced by living organisms as part 
of the hosts innate immunity (Zasloff, 2002). They are expressed on the primary barriers of 
organisms such as the skin or the mucosal epithelial cells (Guan-Guerra et al., 2010). These 
peptides show potent antimicrobial activities against bacteria, viruses and fungi. AMPs have 
antibacterial activity through membrane disruption and pore formation, causing leakage of the 
cellular contents. Additionally, AMPs may enter and interact with intracellular molecules 
within bacteria, thereby inhibiting DNA, RNA and protein synthesis (Peters et al., 2010).  
 
Certain AMPs are amphiphilic (contain hydrophilic and hydrophobic regions). This property 
facilitates AMP penetration into mammalian cells. A number of studies have shown their 
promise as a potential therapy for intracellular infections. One example of an AMP that can 
enter mammalian cells is Cathelicidin LL-37, which is naturally expressed by the human skin. 
Noore et al., demonstrated that LL-37 was effective against intracellular S. aureus in 
osteoblasts (Noore et al., 2013). Temporin, an AMP isolated from frog skin was found to be 
bactericidal against intracellular methicillin-sensitive Staphylococcus aureus (MSSA) and 
MRSA in keratinocytes, and promoted wound healing by stimulating keratinocyte migration 
(Di Grazia et al., 2014). Another study found that equine alpha-helical antimicrobial peptide 
eCATH1 killed Rhodococcus equi in macrophages (Schlusselhuber et al., 2013). Brinch et al., 
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2010 demonstrated that Plectasin, an AMP derived from the pezizalean fungus 
Pseudoplactenia nigrella was effective against intracellular S. aureus in human and mouse 
monocytes (Brinch et al., 2010).  
 
Antisense oligonucleotide based technologies  
Antisense oligonucleotide (AS-ODN) based technology is a platform designed to control gene 
expression at the RNA level. AS-ODNs are short oligomers of nucleic acids or nucleic acid 
mimics; consisting of 10-30 residues that are complimentary to the target mRNA of interest. 
Hybridization of AS-ODN to the target mRNA can inhibit the translation process, resulting in 
repression of gene expression (Sahu et al., 2007). Phosphorothioate (PS), peptide nucleic acid 
(PNA), locked nucleic acid (LNA), and phosphorodiamidate morpholino oligomer (PMO), are 
among the most studied AS-ODNs (Chan et al., 2006). To improve delivery into bacterial or 
mammalian cells, AS-ODNs are often attached to cell penetrating peptides (CPP) (Nekhotiaeva 
et al., 2003).  
 
For antibacterial purposes, AS-ODNs are designed to target genes essential to the survival of 
the bacteria (Good, 2002). In this way, antisense technology serves to silence or completely 
knock-out the function of selected genes. Antisense PNAs and PMOs have been shown to 
effectively inhibit bacterial growth in vitro and in vivo. Good et al., 2001 demonstrated 
bactericidal activity of a peptide-PNA conjugate targeted to the acyl-carrier protein (acp), an 
essential gene involved in fatty acid biosynthesis in E. coli (Good et al., 2001). Similarly, Tilley 
et al., 2007 showed that CPP conjugated PMO targeted to the acp gene reduced bacteremia and 
promoted survival of mice infected with E. coli (Tilley et al., 2007).  
 
For the potential of AS-ODNs to be fully realized, the challenge of delivery across both 
bacterial and mammalian membrane must be overcome. Ma et al., 2014 showed that 
electroporation improved the delivery of a peptide-PNA targeting bacterial RNA polymerase 
and killed intracellular S. typhimurium (Ma et al., 2014). Also, Mitev et al., 2009 introduced 
piperazine (Pip) linkages between bases of PMO, to introduce cationic charges to the peptide-
PMO, to further enhance its delivery into mammalian cells. The Pip-peptide-PMO showed 
potent efficacy against intracellular S. typhimurium and killed > 99% of the bacteria inside 
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macrophages (Mitev et al., 2009). These studies suggest that antisense technology, with further 
improvement on delivery issues; represents a promising strategy against intracellular bacteria. 
 
Nanoparticles  
Nanoparticles are nano-scale materials derived from metallic, metal oxide, semiconductors, 
polymers or carbon-based materials (Hajipour et al., 2012). Nanoparticles have long been 
applied in the material sciences field, but recent evidence suggests that they have potential 
applications in the medicinal field. Certain nanoparticles demonstrate potent antibacterial 
activities and may help to potentiate small molecule antibiotics. For example, Azam et al., 2012 
demonstrated antibacterial activities of Zinc oxide, Cuprum oxide and Ferum oxide 
nanoparticles against Gram +ve and Gram -ve pathogens (Azam et al., 2012).  
 
Nanoparticles display antibacterial activities through various mechanisms. For example, the 
cationic charges of titanium and aluminium oxide nanoparticles promote their adsorption onto 
bacterial surfaces, resulting in destabilization of the membrane, leading to cellular leakage 
(Ruparelia et al., 2008; Pal et al., 2015). Silver nanoparticles can produce free radicals that can 
cause lipid peroxidation of the membrane, resulting in loss of the normal functions, such as 
bacterial respiratory activities (Allahverdiyev et al., 2011). Zinc nanoparticles internalized by 
the bacteria can induce production of reactive oxygen species (ROS), resulting in ROS-
mediated cell damage (Patra et al., 2015; Zhao and Drlica, 2014).  
 
Although nanoparticles are very large structures relative to drug molecules, they are able to 
improve cell entry properties to access intracellular targets. This effect is being exploited in 
several therapeutic areas aiming to improve the intracellular delivery and cell type targeting of 
biomolecules or drugs. Nanoparticles are thought to enter mammalian cells through 
phagocytosis or the endocytosis pathway (Oh and Ji-Ho, 2014). This ability makes 
nanoparticles useful weapons in the fight against intracellular bacteria. Pati et al., 2014 
demonstrated zinc oxide uptake by macrophages. Zinc oxide induced ROS and nitric oxide 
production in the cells and subsequently killed intracellular Mycobacterium smegmatis (Pati et 
al., 2014).  
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Certain nanoparticles such as liposomes, polymeric nanoparticles, solid lipid nanoparticles and 
dendrimers can be tailored to display desired charge or composition for combination with other 
biomolecules; for example, drugs, antibodies, proteins and oligonucleotides. The nanoparticle 
surfaces can also be decorated with material that is responsive to certain stimuli (e.g pH or 
temperature) allowing for controllable drug release in a specific place, for example in the 
acidified endosome (Xu et al., 2006). Therefore, together with the ability to enter mammalian 
cells, the nanoparticle platform can also be utilized to improve the delivery of existing 
antibiotics into host cells (Zhang et al., 2010). A number of studies have investigated the ability 
of nanoparticles to potentiate antibiotic activities against intracellular bacteria and these are 
listed in Table 2. The efficacies of penicillin, gentamicin and tetracycline against intracellular 
S. aureus (Meo et al., 2012; Ranjan et al., 2009; Maya et al., 2012), rifampicin and isoniazid 
against intracellular M. tuberculosis (Clemens et al., 2012), streptomycin and doxycycline 
against intracellular of Brucella melitensis (Seleem et al., 2009) and rifampicin and 
azithromycin against intracellular Chlamydial trachomatis (Toti et al., 2011), have all been 
markedly improved over the free drug by delivering them as nanoparticle conjugates. 
 
Recent advances with a polymeric biocide  
Polyhexamethylene biguanide (PHMB) is a cationic polymer composed of repeating biguanide 
groups linked by hexamethylene chains (Figure 1). PHMB alone is a potent topical 
antimicrobial against Gram +ve and Gram -ve bacteria (Gilbert and Moore, 2005), 
fungi(Messick et al., 1999; Hiti 2002), parasites and viruses (Romanowski et al., 2013). It has 
been widely used as antiseptic in medicine, food industries and domestic applications (Gilbert 
and Moore, 2005). PHMB applications include impregnation in wound dressing (Moore and 
Gray, 2007), water treatment (Kusnetsov et al., 1997), mouthwash and disinfection in contact 
lenses (Hiti, 2002). Although PHMB has been used for over 40 years, there are no reports of 
bacterial resistance towards this compound (Gilbert and Moore, 2005). 
 
PHMB antibacterial activities involve the interaction of biguanide groups with the cytoplasmic 
membrane, lipopolysaccharide and peptidoglycan of the bacterial cell wall. This binding is 
believed to displace the divalent cation Ca2+ causing membrane destabilization and cellular 
leakages (Gilbert and Moore, 2005). Simultaneously, the hexamethylene segment can interact 
with phospholipids on the membrane, causing a phase separation that disturbs random 
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distribution of lipids, further destabilizing the membrane structure (Broxton et al., 1984). 
Furthermore, recent findings in our laboratory demonstrated that PHMB enter bacteria cells 
and this leads to chromosome condensation (Chindera et al., 2016). Therefore, PHMB may 
have at least two mechanisms of action, and this may help to explain why acquired antibacterial 
resistance to PHMB has not yet been reported.  
 
Recent discoveries in our laboratory also demonstrate that PHMB can enter a range of 
mammalian cells and co-localize with intracellular MRSA (Chindera et al., 2016; Firdessa et 
al., 2015; Kamaruzzaman, NF; Firdessa, R; Good 2016). Furthermore, we demonstrated that 
PHMB causes a marked reduction in survival of intracellular MRSA inside the host cells 
(Figure 2). This finding shows, for the first time, that PHMB has potential value to be further 
developed as a novel therapy for intracellular infections. 
 
Summary and outlook 
The discovery of penicillin is considered to be one of the most significant advances in medicine, 
and the subsequent development and use of conventional antibacterials has saved large 
numbers of lives. However, the current problem of antibacterial resistance threatens our ability 
to treat and control infections. Intracellular bacteria, which are generally harder to reach than 
extracellular bacteria, may not be resistant to antibacterials in the conventional sense, yet 
nevertheless represent a population of bacteria that are difficult to treat, resulting in frequent 
treatment failures and limited treatment options. The difficulty of reaching intracellular 
bacteria was recognised over 50 years ago (Holmes et al., 1966) and in this review we have 
discussed the challenges of antibacterial therapy for intracellular infections.  
The outlook for the treatment of intracellular infections is positive. There are a number of new 
technologies that offer promise over conventional treatments. AMPs and AS-ONDs have the 
potential to increase the choice of treatments and offer the advantage that acquired resistance 
to these compounds may be infrequent (Guilhelmelli et al., 2013); however, such technologies 
still face challenges in gaining entry into host cells. The most promising advances in this area 
may be found in the nanoparticle arena, where several studies have shown antibacterials to 
have successful access to and efficacy against bacteria residing within host cells. In this review, 
we have focused on targeting the bacteria however there are also several strategies that target 
the host. One example is the use of statins to improve the outcome of infection with M. 
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tuberculosis. Statins lower host cholesterol by the inhibition of HMG-CoA reductase, an 
enzyme in the cholesterol biosynthetic pathway. The ability to utilise host cholesterol as a 
carbon source is required for M. tuberculosis persistence. Lowering cholesterol levels in the 
host by the use of statins improves clearance of the bacteria by autophagy (Parihar et al., 2014). 
Therefore, interference with the host cellular pathways provides an additional alternative 
strategy in the battle against intracellular bacterial pathogens (Hawn et al., 2015). 
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Biofilm - a structured community of bacterial cells enclosed in a self-produced 
polymeric matrix and adherent to an inert or living surface. 
 
M-cells - highly specialised cells present within the epithelium of the small and 
large intestine. They play a central role in the initiation of mucosal immune 
responses by transporting antigens and microorganisms to the underlying 
lymphoid tissue. 
 
Peyer's patches - are small masses of lymphatic tissue found in the small 
intestine. They monitor intestinal bacteria populations and preventing the growth 
of pathogenic bacteria in the intestines. 
 
Actin - a protein that forms filaments and provides a structural scaffold for cells. 
It is also a component of muscle fibres. 
 
Macrophages – white blood cells that engulf invading pathogens or cells that are 
not recognised as self.  
 
Phagosome - a vacuole in the cytoplasm of a cell, containing an engulfed particle 
enclosed within a part of the cell membrane. 
 
Lysosome - an organelle in the cytoplasm of eukaryotic cells containing 
degradative enzymes enclosed in a membrane. 
 
Cytosol - the aqueous component of the cytoplasm of a cell within which various 
organelles and particles are suspended. 
 
Phagolysosome - the name of the vacuole formed when the phagosome is fused 
with the lysosome and the contents of the lysosome gains access to the bacteria 
residing within.  
 
Exocytosis/endocytosis -   Endocytosis is the process of capturing a substance or 
particle from outside the cell by engulfing it with the cell membrane, and bringing 
it into the cell. Exocytosis describes the process of vesicles fusing with the plasma 







Table 1 Summary of diseases associated with intracellular bacteria 
 
Bacteria Associated disease Host cells 
Localisation 








Gorvel and Méresse, 2001, Brumell 







Armstrong and Hart, 1971; Rohde 
et al., 2012, Watson et al., 2012 
Chlamydia 
species 
Ocular and genital 
infections 
Conjunctiva and genital 
epithelial cells 
Vacuole** Kumar et al., 2006 
Listeria 
monocytogenes 










Brouillette et al., 2003 
Fraunholz and Sinha, 2012 
Escherichia coli Urinary tract infections, 
mastitis. 
Bladder epithelial cells, 
mammary epithelial cells 
Vacuole Dikshit et al., 2015 
 
* Modified phagosome also known as salmonella containing vacuole 
** Vacuole also known as inclusion
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Antibiotic Outcome  Reference 
Macrophages Staphylococcus 
aureus 
Squanelene Penicillin G 
(PenG) 
NP-Pen G killed 87% and free 








Chitosan Tetracycline (Tet) NP-Tet killed ~97% in THP-1 and 
~95% in HEK 293 
Free Tet killed ~83% in THP-1 
and ~85% in HEK 293 







Rifampicin (Rif) NP-Rif reduced 3.3 log 
Free Rif reduced 1.6 log 














NP- Rif reduced 40% and free Rif 
reduced 20% 
NP-Azi reduced 40% and free Azi 
showed no reduction 
















NP-Strep-Dox reduced 0.72 log in 
spleen and 0.79 in liver 
Free Strep-Dox reduced 0.51 log 
in spleen and 0.42 log in liver 
















+Na block copolymers 
Gentamicin 
(Gent) 
NP-Gent reduced 0.29 log in 
spleen and 1.07 log in liver 
Gent only reduced 0.23 log in 
liver but not in spleen (0.34 
increase) 
Ranjan et al., 
2009 
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Figure 1 The structure of PHMB. PHMB is a cationic polymer with a repeating 20-30 units 























Figure 2 Intracellular location and bactericidal activities of nadifloxacin and PHMB 
against intracellular MRSA. (a) Colocalization of PHMB-FITC with EMRSA-15 in 
keratinocytes.  Keratinocytes were infected with EMRSA-15 followed by treatment with 
PHMB-FITC (green). Keratinocytes were labeled with DAPI (blue) and WGA (red). Upper 
panels are images of infected cells and merged images. Lower panels are enlarged images that 
clearly show colocalisation between PHMB-FITC (green) and EMRSA-15 (blue). White scale 
bar is 25 μm (b) Survival of EMRSA-15 within keratinocytes after treatment with 
nadifloxacin and PHMB.  Keratinocytes infected with strains EMRSA-15 were either 
untreated or treated with increasing concentrations of nadifloxacin or PHMB. Untreated 
cultures were used to establish cfu values corresponding to 100% survival. 
 
